companies

Quibim

Founded 2012
Employees 50+
Primary contact
Avenida Aragon 30
13th floor, Office I - J
46021 Valencia
Spain
+34 96 124 32 25
Links
https://quibim.com/
Sections
Technologies
Quibim is a leader in whole-body medical imaging analysis. The company's Quibim Precision imaging ecosystem is used for a wide range of applications, from detecting a disease to tracking the efficacy of novel treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers. By integrating with existing PACS/RIS, the Quibim Precision ecosystem is also meant to speed up the workflow to help radiologists focus on their patients — letting them fully automate post-processing tasks and prioritize their worklist to facilitate patient care. Quibim's partners include major companies such as Janssen, Hitachi, Ferring Pharmaceuticals, Philips, and Nuance.
Select partners: Janssen, Ferring Pharmaceuticals, Philips, Merck, GE Healthcare, IQVIA, El Instituto de Investigación Sanitaria INCLIVA, Hospital Clínico de València.
Founded 2012
Employees 50+
Primary contact
Avenida Aragon 30
13th floor, Office I - J
46021 Valencia
Spain
+34 96 124 32 25
Links
https://quibim.com/
Sections
Technologies

Funding 💰

Total $19.6M
Select investors Adara Ventures, Amadeus Capital Partners, Angels Capital, APEX Ventures, EASME, Partech, Tech Transfer UPV

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Tackling the radiologist shortages: Quibim's AI-enabled tools can help radiologist be more productive, thus helping solve the chronic shortage of radiologists worldwide.
  • Applicable to radiology and biopharma: In addition to reducing radiologists' workload, Quibim solutions can also help biopharma companies to develop treatments and drugs more efficiently. In fact, the biopharma industry relies more and more on medical images and is increasingly dictated and regulated by evidence-based guidelines. 🔗
  • Cleared by the FDA: In March 2021, Quibim received FDA 510(k) clearance for qp-Prostate, its AI solution for prostate MRI analysis that aims to increase diagnostic accuracy and, potentially, early prostate cancer detection, which may contribute to long term survival. 🔗
  • Rapid adoption: "Quibim's rapid adoption is an indicator of how innovative doctors and researchers are eager to have access to and exploit AI technology and methods that can automatically recognise complex patterns in imaging data, to get quantitative assessments and improve the service they provide" - Rocio Pillado, partner at Adara Ventures. 🔗
  • Helping fight COVID-19: "Quibim's all-in-one platform is the answer that radiologists have been waiting for and we look forward to helping them grow internationally while continuing the fight against COVID-19 and other life-threatening conditions" - Pierre Socha, Partner at Amadeus Capital Partners. 🔗

Video ▶️

Last update: August 16, 2022